Medicare Enrolled

Dr. Josep Genebriera De Lamo, M.D.

Student in an Organized Health Care Education/Training Program · Jacksonville, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
1551 RIVERSIDE AVE, Jacksonville, FL 32204
9043544488
In practice since 2008 (17 years)
NPI: 1548418346 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Genebriera De Lamo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Genebriera De Lamo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Genebriera De Lamo

Dr. Josep Genebriera De Lamo is a student in an organized health care education/training program in Jacksonville, FL, with 17 years in practice. Based on federal Medicare data, Dr. Genebriera De Lamo performed 12,944 Medicare services across 6,829 unique beneficiaries.

Between the years covered by Open Payments, Dr. Genebriera De Lamo received a total of $175,366 from 44 pharmaceutical and/or device companies across 1485 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Genebriera De Lamo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 1% volume in FL$ $175,366 industry payments

Medicare Practice Summary

Medicare Utilization ↗
12,944
Medicare services
Top 1% in FL for student in an organized health care education/training program
6,829
Unique beneficiaries
$45
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~761 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Destruction of precancerous skin growths, 2-144,847$5$25
Office visit, established patient (20-29 min)2,209$60$318
Destruction of precancerous skin growth, 11,257$34$245
Skin biopsy, tangential1,063$63$380
Destruction of skin growths (warts/lesions), 1-14802$78$420
Office visit, established patient (30-39 min)730$85$446
Biopsy of related skin growth, each additional growth381$39$189
Steroid injection (triamcinolone)259$1$4
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm191$225$1,113
New patient office visit (30-44 min)160$72$393
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm150$97$891
Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm120$129$702
New patient office visit (45-59 min)106$111$582
Destruction of precancer skin growth, 15 or more growths86$125$617
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less81$190$978
Drug injection, under skin or into muscle79$10$51
Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm63$67$634
Office visit, established patient (10-19 min)63$40$201
Biopsy of ear44$55$355
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)34$300$1,175
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm33$112$1,009
Injection into skin growth, 1-7 growths30$34$207
Removal of noncancer skin growth of body, arms, or legs, 0.6-1.0 cm25$60$577
Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm23$101$919
Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm20$140$756
Application of light to destroy precancer skin growth18$74$551
Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 2.1-3.0 cm16$188$871
Punch biopsy, first skin growth14$96$472
Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm14$238$1,139
Application of light with debridement to destroy precancer skin growth14$218$1,074
Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm12$362$1,719
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$175,366
Total received (2018-2024)
Avg $25,052/year across 7 years
Top 0% in FL for student in an organized health care education/training program
44
Companies
1,485
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$154,389 (88.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,977 (12.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$15,210
2023
$7,143
2022
$13,831
2021
$10,897
2020
$9,610
2019
$75,202
2018
$43,472

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AbbVie, Inc.
$112,995
ABBVIE INC.
$16,017
AbbVie Inc.
$15,686
Galderma Laboratories, L.P.
$11,147
GENZYME CORPORATION
$2,164
Janssen Biotech, Inc.
$2,021
Novartis Pharmaceuticals Corporation
$1,636
Dermavant Sciences, Inc.
$1,464
Mayne Pharma Inc.
$1,349
Regeneron Healthcare Solutions, Inc.
$1,259
LEO Pharma Inc.
$1,210
Lilly USA, LLC
$848
Amgen Inc.
$821
PFIZER INC.
$741
E.R. Squibb & Sons, L.L.C.
$740
Arcutis Biotherapeutics, Inc.
$702
UCB, Inc.
$611
Ortho Dermatologics, a division of Bausch Health US, LLC
$552
MAYNE PHARMA INC.
$443
Incyte Corporation
$413
Sun Pharmaceutical Industries Inc.
$409
SUN PHARMACEUTICAL INDUSTRIES INC.
$387
VYNE Pharmaceuticals Inc.
$199
Journey Medical Corporation
$159
Almirall LLC
$136
Celgene Corporation
$129
Allergan Inc.
$123
Encore Dermatology Inc.
$114
DERMIRA, INC.
$102
Sandoz Inc.
$96
Mylan Pharmaceuticals Inc.
$91
MAYNE PHARMA COMMERCIAL LLC
$89
Allergan, Inc.
$81
EPI Health, LLC
$79
PruGen, Inc. Pharmaceuticals
$52
Biofrontera Inc.
$50
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Bayer HealthCare Pharmaceuticals Inc.
$40
DUSA Pharmaceuticals, Inc.
$37
Taro Pharmaceuticals USA, Inc.
$33
Smith & Nephew, Inc.
$28
Genentech USA, Inc.
$27
Verrica Pharmaceuticals Inc.
$22
Promius Pharma LLC
$18
Top 3 companies account for 82.5% of total payments
Associated products mentioned in payments ›
0.25% · 20% · ABSORICA (isotretinoin) · ABSORICA LD · ADBRY · AKLIEF · ALTRENO · AMZEEQ · ARAZLO · Absorica LD · Ameluz · BLU-U · BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 · BOTOX · BOTOX COSMETIC · BRYHALI · Bimzelx · CIBINQO · CLODERM · COSENTYX · Cabtreo · Cimzia · Clindamycin Phosphate and Benzoyl Peroxide · DORYX · DUOBRII · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ENSTILAR · EPIDUO FORTE · EUCRISA · Enbrel · Erivedge · Exelderm · FINACEA · Finacea · HUMIRA · Humira · ILUMYA · ILUMYA (tildrakizumab-asmn) injection · Ilumya · Impoyz · JUBLIA · KERYDIN · LIBTAYO · Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution · ONEXTON · OPZELURA · ORACEA · Olux · Otezla · QBREXZA · REMICADE · RINVOQ · SILIQ · SKYRIZI · SOOLANTRA · SPEVIGO · STELARA · Santyl · Seysara · Sitavig · Skyrizi · Sotyktu · TALTZ · TOPICORT (desoximetasone) Topical Spray · TREMFYA · TWYNEO · TargaDox · Tremfya · Trianex · VTAMA · Winlevi · Xolair · YCANTH · ZILXI · Zoryve
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (88%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in student in an organized health care education/training program and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for student in an organized health care education/training program in FL.

Equivalent to $1,355 per 100 Medicare services performed
Looking for a student in an organized health care education/training program in Jacksonville?
Compare student in an organized health care education/training programs in the Jacksonville area by procedure volume, costs, and industry payment transparency.
Browse student in an organized health care education/training programs nearby

Geographic Context

Student in an Organized Health Care Education/Training Programs within 10 mi
1,071
Per 100K population
106.3
County median income
$68,447
Nearest hospital
ASCENSION ST VINCENT'S RIVERSIDE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Genebriera De Lamo is a clinical cardiology specialist, with above-average Medicare volume (top 1% in FL), and high industry engagement (speaking/promotional, top 0%), with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Genebriera De Lamo experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Genebriera De Lamo performed 4,847 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Genebriera De Lamo receive payments from pharmaceutical companies?
Yes. Dr. Genebriera De Lamo received a total of $175,366 from 44 companies across 1,485 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Genebriera De Lamo's costs compare to other student in an organized health care education/training programs in Jacksonville?
Dr. Genebriera De Lamo's average Medicare payment per service is $45. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Genebriera De Lamo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →